Skip to main content

Argenx SE (ARGX)

NASDAQ: ARGX · IEX Real-Time Price · USD
294.17 -1.85 (-0.62%)
Oct 21, 2021 4:00 PM EDT - Market closed
Market Cap15.17B
Revenue (ttm)44.42M
Net Income (ttm)-645.03M
Shares Out51.40M
EPS (ttm)-6.89
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume97,795
Open295.99
Previous Close296.02
Day's Range293.15 - 298.35
52-Week Range244.98 - 382.15
Beta0.81
AnalystsBuy
Price Target346.76 (+17.9%)
Est. Earnings DateOct 28, 2021

About ARGX

argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indic...

IndustryBiotechnology
IPO DateMay 18, 2017
CEOTim Van Hauwermeiren
Employees336
Stock ExchangeNASDAQ
Ticker SymbolARGX
Full Company Profile

Financial Performance

In 2020, Argenx SE's revenue was 36.43 million, a decrease of -47.80% compared to the previous year's 69.78 million. Losses were -528.92 million, 224.6% more than in 2019.

Financial numbers in millions EURFinancial Statements

Analyst Forecast

According to 17 analysts, the average rating for Argenx SE stock is "Buy." The 12-month stock price forecast is 346.76, which is an increase of 17.88% from the latest price.

Price Target
$346.76
(17.88% upside)
Analyst Consensus: Buy

News

argenx to Report Third Quarter 2021 Financial Results and Business Update on October 28, 2021

October 21 , 202 1 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer,...

15 hours ago - GlobeNewsWire

argenx to Highlight Potential First-in-Class FcRn Antagonist Efgartigimod at Upcoming Neuromuscular Meetings

Breda, the Netherlands – October 8 , 2021 – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancers...

1 week ago - GlobeNewsWire

argenx to Present at Upcoming Investor Conferences

September 3, 2021 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, ...

1 month ago - GlobeNewsWire

argenx Announces Validation of European Marketing Authorization Application for Efgartigimod in Generalized Myastheni...

Breda, the Netherlands – August 2 5 , 2021 – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer...

1 month ago - GlobeNewsWire

argenx to Present at 2021 Wedbush PacGrow Virtual Healthcare Conference

August 4, 2021 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, tod...

2 months ago - GlobeNewsWire

Recap: argenx Q2 Earnings

Shares of argenx (NASDAQ:ARGX) decreased 4.8% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 162.86% over the past year to $1.98, which may not co...

2 months ago - Benzinga

argenx Reports Half Year 2021 Financial Results and Provides Second Quarter Business Update

- Completion of enrollment expected by year-end for ADAPT-SC and ADVANCE (IV) trials of efgartigimod; topline data for both trials expected in first half of 2022

2 months ago - GlobeNewsWire

argenx to Report Half Year 2021 Financial Results and Second Quarter Business Update on July 29, 2021

July 22, 2021 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, toda...

2 months ago - GlobeNewsWire

argenx to Host Virtual R&D Day on July 20, 2021

July 14, 2021 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, toda...

3 months ago - GlobeNewsWire

argenx announces publication of Phase 3 ADAPT trial results of efgartigimod for the treatment of generalized myasthen...

Results from ADAPT showed treatment with efgartigimod provided clinically meaningful improvement s in strength and quality of life measures in g eneralized m yasthenia g ravis (gMG )

4 months ago - GlobeNewsWire

argenx (ARGX) to Regain AML Candidate After J&J's Dismissal

argenx (ARGX) is developing cusatuzumab as potential treatment for acute myeloid leukemia. However, its partner, J&J, decided to discontinue the development agreement with the company for the candidate.

4 months ago - Zacks Investment Research

Argenx Regains Global Rights from Johnson & Johnson to Blood Cancer Candidate Cusatuzumab

Johnson & Johnson (NYSE: JNJ) has walked away from a $1.6 billion blood cancer candidate deal with Argenx SE (NASDAQ: ARGX) for the CD70-targeting cusatuzumab. The pair first came together to develop th...

Other symbols:JNJ
4 months ago - Benzinga

argenx to regain global rights to cusatuzumab

Regulated Information/Inside Information

4 months ago - GlobeNewsWire

argenx Appoints Karl Gubitz as Chief Financial Officer

June 1, 2021 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today...

4 months ago - GlobeNewsWire

argenx to Present at Upcoming Investor Conferences

June 1, 2021 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today...

4 months ago - GlobeNewsWire

Recap: argenx Q1 Earnings

Shares of argenx (NASDAQ:ARGX) were unchanged after the company reported Q1 results. Quarterly Results Earnings per share increased 60.68% year over year to ($0.81), which may not compare to the estimat...

5 months ago - Benzinga

argenx Reports First Quarter 2021 Financial Results and Provides Business Update

Japanese Marketing Authorization Application (J-MAA) for efgartigimod accepted for review by Japan's Pharmaceuticals and Medical Device Agency (PMDA) for generalized myasthenia gravis (gMG)

5 months ago - GlobeNewsWire

argenx's Earnings Outlook

argenx (NASDAQ:ARGX) releases its next round of earnings this Friday, May 14. Here is Benzinga's essential guide to argenx's Q1 earnings report.

5 months ago - Benzinga

argenx announces results of Annual General Meeting of Shareholders

May 1 1 , 20 2 1 Breda, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer...

5 months ago - GlobeNewsWire

argenx to Report First Quarter 2021 Financial Results and Business Update on May 14, 2021

May 7, 2021 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today ...

5 months ago - GlobeNewsWire

argenx Management to Present at Upcoming Virtual Investor Conferences

April 28, 2021 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, tod...

5 months ago - GlobeNewsWire

7 Pharmaceutical Stocks Working on Their Next Blockbuster

Pharmaceutical stocks are a sector with unique success factors. One factor is developing blockbuster drugs.

Other symbols:BHVNBMRNMRTXNVONVS
7 months ago - InvestorPlace

argenx: Q4 Earnings Insights

Shares of argenx (NASDAQ:ARGX) fell 3.2% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share were down 60.08% year over year to ($4.21), which missed the es...

7 months ago - Benzinga

argenx Reports Full Year 2020 Financial Results and Provides Fourth Quarter Business Update

- Biologics License Application (BLA) for IV efgartigimod accepted for review by U.S. Food and Drug Administration (FDA) for generalized myasthenia gravis (gMG)

7 months ago - GlobeNewsWire